JNJ vs DXCM
By Alex · Tickerpine
Johnson & Johnson vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | DXCM |
|---|---|---|
| Price | $260.86 | $90.80 |
| Market cap | $628.65B | $34.26B |
| P/E ratio | 30.3 | 35.9 |
| ROE | 25.74% | 38.49% |
| Profit margin | 21.48% | 20.12% |
| Revenue growth | 6.60% | 13.10% |
| Dividend yield | 2.05% | — |
| Beta | 0.23 | 1.41 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs DXCM in plain English
- JNJ is the bigger company — about 18.3× the market cap of DXCM.
- JNJ is cheaper on earnings (P/E 30.3 vs 35.9).
- DXCM earns a higher return on equity (38% vs 26%).
- DXCM is growing revenue faster (13% vs 7%).
- JNJ pays a dividend (2.05%) while the other effectively doesn't.
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.